A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence

Drug and Alcohol Review

Volumn 33, Issue 2, 2014, Pages 115-128

  Larney, Sarah ^a,b   Gowing, Linda ^c   Mattick, Richard P ^a   Farrell, Michael ^a   Hall, Wayne ^d   Degenhardt, Louisa ^a,e  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Heroin; Investigational therapies; Naltrexone; Opioid dependence; Systematic review

Indexed keywords

DIAMORPHINE; NALTREXONE; NARCOTIC ANTAGONIST;

DRUG IMPLANT; HUMAN; INVESTIGATIONAL THERAPIES; META ANALYSIS; OPIATE ADDICTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

HEROIN; INVESTIGATIONAL THERAPIES; NALTREXONE; OPIOID DEPENDENCE; SYSTEMATIC REVIEW;

DRUG IMPLANTS; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84897602802     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/dar.12095     Document Type: Review

References (32)

1. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011;4:CD001333.
2. Krupitsky E, Zvartau E, Woody GE. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep 2010;12:448-453.
3. Lobmaier P, Kornør H, Kunøe N, Bjørndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008;(2):CD006140.
4. NHMRC: National Health and Medical Research Council. Naltrexone implant treatment for opioid dependence. Canberra: National Health and Medical Research Council, 2010.
5. Reece AS. Epidemiologic and molecular pathophysiology of chronic opioid dependence and the place of naltrexone extended-release formulations in its clinical management. Subst Abuse 2012;6:115-133.
6. Kelty E, Hulse G. Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use. Addiction 2012;107:1817-1824.
7. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
8. Higgins JPT, Green S, eds. 2011. Cochrane handbook for systematic review of interventions version 5.1.0. Available at: http://www.cochrane-handbook.org (accessed August 2013).
9. Cochrane Collaboration. Review Manager (RevMan) Version 5.2. 5.0 ed. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2012.
10. Gowing L, Ali R, White JM. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst Rev 2010;1:CD002022.
11. Balshem H, Helfand M, Schunemann HJ, etal. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-406.
12. Krupitsky E, Zvartau E, Blokhina E, etal. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry 2012;69:973-981.
13. Tiihonen J, Krupitsky E, Verbitskaya E, etal. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 2012;169:531-536.
14. Hulse G, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry 2009;66:1108-1115.
15. Kunøe N, Lobmaier P, Vederhus JK, etal. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2009;194:541-546.
16. Lobmaier P, Kunøe N, Gossop M, Katevoll T, Waal H. Naltrexone implants compared to methadone: outcomes six months after prison release. Eur Addict Res 2010;16:139-145.
17. Tait RJ, Ngo HTT, Hulse G. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat 2008;35:116-124.
18. Ngo HTT, Tait RJ, Hulse GK. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation. Arch Gen Psychiatry 2008;65:457-465.
19. Reece AS. Favorable mortality profile of naltrexone implants for opiate addiction. J Addict Dis 2010;29:30-50.
20. Lobmaier PP, Kunoe N, Wall H. Treatment research in prison: problems and solutions in a randomized trial. Addiction Res Theor 2010;18:1-13.
21. Ngo HTT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse G. Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:23-28.
22. Hulse G, Arnold-Reed DE, O'Neil G, Chan CT, Hansson RC, O'Neil P. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 2004;9:59-65.
23. Wolfe D, Carrieri MP, Dasgupta N, Wodak A, Newman R, Bruce RD. Concerns about injectable naltrexone for opioid dependence. Lancet 2011;377:1468-1470.
24. World Medical Association. 2013. Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/e/policy/pdf/17c.pdf (accessed August 2013).
25. WHO: World Health Organization. WHO model list of essential medicines. Geneva: World Health Organization, 2013. [accessed September 2013] (Available at: http://www.who.int/medicines/publications/essentialmedicines/en/).
26. Bale RN, Van Stone WW, Kuldau JM, Engelsing TMJ, Elashoff RM, Zarcone VP. Therapeutic communities vs methadone maintenance. A prospective controlled study of narcotic addiction treatment: design and one year follow-up. Arch Gen Psychiatry 1980;37:179-193.
27. Thomson CL, Morley KC, Teesson M, Sannibale C, Haber PS. Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. Drug Alcohol Rev 2008;27:115-122.
28. Kelty E, Ngo HT, Hulse G. Assessing the usefulness of health data linkage in obtaining adverse event data in a randomised controlled trial of oral and implant naltrexone in the treatment of heroin dependence. Clin Trials 2012;10:170-180.
29. Waal H, Frogopsahl G, Olsen L, Christophersen AS, Mørland J. Naltrexone implants-duration, tolerability and clinical usefulness: a pilot study. Eur Addict Res 2006;12:138-144.
30. Australasian Chapter of Addiction Medicine of the Royal Australasian College of Physicians. Position statement on the use of sustained release formulations of naltrexone in opioid dependence. Royal Australasian College of Physicians; 2013. Available at: http://www.racp.edu.au/index.cfm?objectid=2088B865-B608-1312-3DE57C28E5CED0A7 (accessed September 2013).
31. Merlo LJ, Greene WM. Pomm R. Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practice. J Addict Med 2011;5:279-283.
32. Roth A, Hogan I, Farren C. Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. J Subst Abuse Treat 1997;14:19-22.